Reverse: 1999 is a gacha game. Players will pull from active Banners that offer a selection of featured characters ranging in rarity. The rarity of these characters is typically tethered to their ...
About five years ago, I ran into a problem many people face as they get older: The people I holiday shop for typically just buy everything they want throughout the year. That, of course, left me ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past? A healthy ...
About five years ago, I ran into a problem many people face as they get older: The people I holiday shop for typically just buy everything they want throughout the year. That, of course, left me ...
Researchers uncovered how fatty molecules called ceramides trigger acute kidney injury by damaging the mitochondria that power kidney cells. By altering ceramide metabolism or using a new drug ...
Researchers used supramolecular nanoparticles to repair the brain’s vascular system and reverse Alzheimer’s in mice. Instead of carrying drugs, the nanoparticles themselves triggered natural clearance ...
Retirement looks different now than it did for previous generations. While it was common at one point to arrive at your golden years with a robust pension, a paid-off home and enough savings to ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
When I was growing up, I relished the chance to show my friends that Queen’s “Another One Bites the Dust” had a hidden message. When played backward, you can hear Freddie Mercury say, “It’s fun to ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback